The CANTOS trial provides strong support for the significance of IL‐1β in atherosclerosis, as therapeutic IL‐1β neutralization in patients with established atherosclerotic disease significantly reduces the incidence of recurrent cardiovascular events.130. The gene discussed is IL1B; the disease is atherosclerosis.